Fri, Sep 26, 2025
Volume 11, Issue 3 (Summer 2025)
Caspian J Neurol Sci 2025, 11(3): 237-244 |
Back to browse issues page
Ethics code: IR.GUMS.REC.1399.615.
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khoshtarash H, Saberi A, Hatamian H, Ashraf A, Ahmadi S, Yazdanipour M A. The Association Between Recombinant Tissue Plasminogen Activator and Post-ischemic Stroke Seizure: A Retrospective Cohort Study. Caspian J Neurol Sci 2025; 11 (3) :237-244
URL: http://cjns.gums.ac.ir/article-1-780-en.html
URL: http://cjns.gums.ac.ir/article-1-780-en.html
Hanie Khoshtarash *1 
, Alia Saberi2 , Hamidreza Hatamian2 , Ali Ashraf3 , Somayeh Ahmadi4 , Mohammad Ali Yazdanipour5
, Alia Saberi2 , Hamidreza Hatamian2 , Ali Ashraf3 , Somayeh Ahmadi4 , Mohammad Ali Yazdanipour5
1- Department of Neurology, Neurosciences Research Center, Faculty of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran. , Haniekhoshtarash@yahoo.com
2- Department of Neurology, Neurosciences Research Center, Faculty of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
3- Clinical Research Development Unit, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
4- Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5- Neuroscience Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran.
2- Department of Neurology, Neurosciences Research Center, Faculty of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
3- Clinical Research Development Unit, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
4- Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5- Neuroscience Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran.
Abstract: (272 Views)
Background: Recombinant tissue plasminogen activator (r-tPA) has remained the primary therapeutic intervention for ischemic stroke when administered within the recommended time window. Despite its well-established benefits, potential side effects—glutamate release, increased leukocyte activity, and oxidative stress—should also be considered. Among these concerns, the development of post-stroke seizures (PSS) has gained attention as a possible complication.
Objectives: This study explored the association between r-tPA administration and the likelihood of post-stroke seizure.
Materials & Methods: A retrospective cohort of 200 patients, split evenly between those treated with r-tPA and those who were not, was analyzed at an academic hospital in northern Iran over three years (2017–2020). Clinical parameters were collected and compared, including demographics, medical history, involved artery, NIHSS (the National Institutes of Health Stroke scale) values on admission, the Alberta stroke program early CT score (ASPECTS), and post-stroke seizure occurrence.
Results: Nineteen patients (10%) developed seizures; 8 of them (8%) belonged to the group without r-tPA, and 11(11%) belonged to the r-tPA group (P=0.469). Results showed no significant relationship between developing seizures and r-tPA therapy. This study shows that the ASPECT score is the only parameter associated with the risk of post-stoke seizure. By increasing one score in ASPECTS, the rate of seizure occurrence decreases by 24.
Conclusion: These outcomes confirm the continued use of r-tPA as a safe and effective treatment option for ischemic stroke patients.
Objectives: This study explored the association between r-tPA administration and the likelihood of post-stroke seizure.
Materials & Methods: A retrospective cohort of 200 patients, split evenly between those treated with r-tPA and those who were not, was analyzed at an academic hospital in northern Iran over three years (2017–2020). Clinical parameters were collected and compared, including demographics, medical history, involved artery, NIHSS (the National Institutes of Health Stroke scale) values on admission, the Alberta stroke program early CT score (ASPECTS), and post-stroke seizure occurrence.
Results: Nineteen patients (10%) developed seizures; 8 of them (8%) belonged to the group without r-tPA, and 11(11%) belonged to the r-tPA group (P=0.469). Results showed no significant relationship between developing seizures and r-tPA therapy. This study shows that the ASPECT score is the only parameter associated with the risk of post-stoke seizure. By increasing one score in ASPECTS, the rate of seizure occurrence decreases by 24.
Conclusion: These outcomes confirm the continued use of r-tPA as a safe and effective treatment option for ischemic stroke patients.
Type of Study: Research |
Subject:
Special
Received: 2025/03/17 | Accepted: 2025/06/13 | Published: 2025/07/1
Received: 2025/03/17 | Accepted: 2025/06/13 | Published: 2025/07/1
Send email to the article author
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
